The content on this site is intended for healthcare professionals only
Cancer journeys: Research from India
Depression in cancer
Managing 'fear of recurrence' of cancer patients
Psychological issues in familial cancer
3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma
PD-1–refractory advanced melanoma: how do we get to the finish line?
Highlights in melanoma from ASCO 2024
ASCO 2024: Highlights and analysis
Melanoma outcomes improved by dual immunotherapy before surgery rather than after
Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
